BridgeBio Pharma Inc (NASDAQ: BBIO) kicked off on Friday, down -1.95% from the previous trading day, before settling in for the closing price of $34.85. Over the past 52 weeks, BBIO has traded in a range of $21.62-$39.54.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 574.82% over the last five years. While this was happening, its average annual earnings per share was recorded -7.21%. With a float of $155.35 million, this company’s outstanding shares have now reached $189.83 million.
The firm has a total of 730 workers. Let’s measure their productivity. In terms of profitability, gross margin is 96.95%, operating margin of -547.57%, and the pretax margin is -528.55%.
BridgeBio Pharma Inc (BBIO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BridgeBio Pharma Inc is 8.11%, while institutional ownership is 77.16%. The most recent insider transaction that took place on May 02 ’25, was worth 39,509. In this transaction Chief Accounting Officer of this company sold 1,026 shares at a rate of $38.51, taking the stock ownership to the 147,639 shares. Before that another transaction happened on May 02 ’25, when Company’s Director sold 100,000 for $38.50, making the entire transaction worth $3,849,900. This insider now owns 105,583 shares in total.
BridgeBio Pharma Inc (BBIO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.21% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Take a look at BridgeBio Pharma Inc’s (BBIO) current performance indicators. Last quarter, stock had a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.53, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -1.95 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Analysing the last 5-days average volume posted by the [BridgeBio Pharma Inc, BBIO], we can find that recorded value of 3.47 million was better than the volume posted last year of 3.11 million. As of the previous 9 days, the stock’s Stochastic %D was 14.87%. Additionally, its Average True Range was 1.74.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 62.18%, which indicates a significant increase from 10.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.38% in the past 14 days, which was lower than the 57.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.36, while its 200-day Moving Average is $29.53. Now, the first resistance to watch is $35.13. This is followed by the second major resistance level at $36.09. The third major resistance level sits at $36.58. If the price goes on to break the first support level at $33.68, it is likely to go to the next support level at $33.19. Now, if the price goes above the second support level, the third support stands at $32.23.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
The company with the Market Capitalisation of 6.49 billion has total of 189,881K Shares Outstanding. Its annual sales at the moment are 221,900 K in contrast with the sum of -535,760 K annual income. Company’s last quarter sales were recorded 116,630 K and last quarter income was -167,420 K.
